Zimmer Biomet (NYSE:ZBH) SVP Sells $250,849.00 in Stock

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the sale, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Zimmer Biomet Stock Performance

ZBH stock traded up $0.16 during trading on Monday, hitting $93.36. 1,955,739 shares of the company traded hands, compared to its average volume of 2,280,309. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The company has a market cap of $18.27 billion, a PE ratio of 26.37, a P/E/G ratio of 1.90 and a beta of 0.58. The stock’s 50-day simple moving average is $92.40 and its 200 day simple moving average is $95.11. Zimmer Biomet Holdings, Inc. has a 1 year low of $84.59 and a 1 year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.04. The firm had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business’s revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ZBH. M&T Bank Corp raised its position in shares of Zimmer Biomet by 15,705.6% in the fourth quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider’s stock valued at $321,158,000 after buying an additional 3,548,998 shares during the last quarter. Dodge & Cox raised its holdings in Zimmer Biomet by 12.9% in the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after acquiring an additional 2,533,009 shares during the last quarter. Norges Bank purchased a new position in Zimmer Biomet in the 2nd quarter worth approximately $225,867,000. Franklin Resources Inc. boosted its holdings in shares of Zimmer Biomet by 43.2% during the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after purchasing an additional 2,017,857 shares during the last quarter. Finally, Auto Owners Insurance Co grew its position in shares of Zimmer Biomet by 8,892.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider’s stock valued at $180,713,000 after purchasing an additional 1,987,362 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of recent analyst reports. TD Cowen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. UBS Group reissued a “sell” rating and issued a $89.00 price target on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and boosted their price target for the stock from $94.00 to $120.00 in a report on Monday, January 5th. Wells Fargo & Company increased their price objective on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a report on Wednesday, February 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $106.20.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.